Last updated: February 26, 2026
What Is TLANDO and Its Commercial Context?
TLANDO (testosterone undecanoate) is an oral testosterone replacement therapy (TRT) approved by the FDA in 2019 for primary and secondary hypogonadism in adult males. Its unique formulation benefits include improved patient adherence due to oral administration, contrasting with injectable or transdermal options.
The global TRT market was valued at approximately USD 2.07 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 5.3% through 2027. Key competitive products include injectable testosterone, gels, patches, and newer oral formulations. TLANDO's differentiated oral delivery positions it as a strategic player, with emphasis on excipient choice impacting bioavailability, stability, and patient tolerability.
What Are the Core Components of TLANDO’s Excipient Strategy?
1. Base Formulation and Carriers
-
Carrier Oil: TLANDO uses a triglyceride-based carrier to facilitate absorption of testosterone undecanoate. Medium-chain triglycerides (MCTs) are common due to their solubility and lipid-soluble drug compatibility.
-
Absorption Enhancers: Some formulations include excipients enhancing gastrointestinal absorption. For testosterone undecanoate, self-emulsifying drug delivery systems (SEDDS) improve bioavailability. Inclusion of surfactants such as polysorbates may aid in emulsification within the GI tract.
2. Solubilizing Agents
- Testosterone undecanoate's lipophilicity requires solubilizing agents. Hydrophilic solvents or surfactants stabilize the compound, optimizing dissolution and absorption.
3. Stabilizers and pH Modulators
- To ensure chemical stability, antioxidants (e.g., butylated hydroxytoluene) prevent oxidation.
- pH modifiers maintain formulation stability, prevent hydrolysis, and optimize drug solubility.
4. Disintegrants and Fillers
- Oral formulations include disintegrants like sodium starch glycolate or croscarmellose sodium, facilitating capsule or tablet breakage for release.
- Fillers such as microcrystalline cellulose ensure uniform weight and ease of manufacturing.
5. Coatings and Binders
- Enteric coatings may be assigned to capsule shells to prevent gastric degradation.
- Binders like polyvinylpyrrolidone (PVP) enhance capsule integrity.
How Does Excipient Choice Affect Commercial Aspects?
Bioavailability and Efficacy
- The selected excipients directly influence testosterone undecanoate's absorption rate, impacting dosing frequency and potency.
- Variations in excipient composition can lead to inconsistent absorption, affecting clinical outcomes and leading to regulatory scrutiny.
Tolerability and Safety Profile
- Excipients like surfactants and carriers can cause gastrointestinal or hypersensitivity reactions.
- Ensuring low reactogenicity while maintaining bioavailability influences market acceptance.
Manufacturing and Scalability
- Excipients with consistent supply, long shelf life, and compatibility with large-scale manufacturing reduce costs and mitigate supply chain risks.
- Use of proprietary excipients or novel carriers can create barriers to entry for competitors.
Regulatory Considerations
- The choice of excipients must meet FDA and EMA safety standards, especially for oral hormonal therapies.
- Novel excipients or delivery systems may require additional validation, impacting time-to-market.
Commercial Opportunities Arising from Excipient Innovation
Enhanced Bioavailability Technologies
- Developing proprietary SEDDS or lipid-based systems offers a competitive edge.
- Patented excipient combinations can secure exclusivity, allowing premium pricing.
Patient-Centric Formulation Development
- Excipient choices that reduce side effects (e.g., fewer GI disturbances) improve adherence.
- Formulations tailored for specific populations (e.g., elderly, hepatic impairment) open niche markets.
Strategic Partnerships and Licensing
- Collaboration with excipient manufacturers can ensure access to cutting-edge delivery systems.
- Licensing novel excipients for testosterone formulations expands market reach.
Supply Chain Differentiation
- Establishing relationships with reliable excipient suppliers secures production continuity.
- Developing formulations with excipients that have broad regulatory acceptance minimizes approval hurdles.
Summary of Key Excipient Components and Strategies
| Component |
Purpose |
Impact |
| MCTs |
Facilitate absorption of lipophilic testosterone undecanoate |
Enhances bioavailability |
| Surfactants (polysorbates) |
Improve emulsification |
Boosts absorption efficiency |
| Antioxidants |
Maintain chemical stability |
Ensures shelf life |
| Disintegrants |
Promote capsule/tablet disintegration |
Improves drug release |
| Enteric coatings |
Protect against gastric degradation |
Improves bioavailability |
Conclusion
TLANDO’s excipient strategy centers on lipid-based carriers, absorption enhancers, and stability agents to optimize oral testosterone delivery. Innovation in excipient selection can drive increased bioavailability, improve tolerability, and reduce manufacturing costs. These factors collectively present opportunities for differentiation and expansion within the competitive TRT market.
Key Takeaways
- Excipient choice impacts TLANDO’s absorption, stability, tolerability, and manufacturing cost.
- Lipid-based carriers and emulsification systems are essential for oral testosterone undecanoate efficacy.
- Patent protections around proprietary excipient combinations can provide a competitive advantage.
- Formulations designed for improved patient experience can expand market share.
- Regulatory compliance for excipient safety is critical in maintaining product approval and market access.
FAQs
Q1: What role do excipients play in the bioavailability of TLANDO?
A1: Excipients like lipid carriers and surfactants enhance solubilization and absorption of testosterone undecanoate in the GI tract, directly influencing bioavailability.
Q2: Can innovative excipient systems extend TLANDO’s market exclusivity?
A2: Yes, proprietary excipient combinations or delivery systems can be patented, providing exclusivity and competitive advantage.
Q3: How do excipients influence the tolerability of oral testosterone formulations?
A3: Excipients can cause side effects like gastrointestinal discomfort; selecting biocompatible, low-irritation components improves tolerability.
Q4: Are there supply chain risks related to excipient choices in TLANDO?
A4: Yes, reliance on proprietary or scarce excipients can pose risks; using widely available, approved excipients reduces this concern.
Q5: What regulatory challenges are associated with excipients in TLANDO?
A5: Excipients must meet safety standards set by agencies like FDA and EMA; introducing novel excipients necessitates additional testing and approval.
References
[1] Statista. (2023). Testosterone replacement therapy (TRT) market size.
[2] U.S. Food and Drug Administration. (2019). TLANDO (testosterone undecanoate) prescribing information.
[3] Zhao, J., & Li, Y. (2021). Lipid-based drug delivery systems for oral testosterone therapy. Journal of Pharmaceutical Sciences, 110(3), 1017–1028.
[4] EMA. (2022). Guidelines on the stability testing of new drug substances and products.
